? ? The Clinical Trials Unit (CTU) at DSC was the number one performing Unit for relative cost per weighted accrual for the past 5 years, number two for % enrollment of minorities for the past three years and number two for overall accrual during the past 12 months (through 6/05). There are currently 103 study subjects on ACTG studies at USC. There are 63% Latinos and 27% women of the nearly 3000 patients attending the Rand Schrader Clinic, site of the USC CTU and CRS, which closely replicates our accrual to aACTG studies. The Site Evaluation Subcommittee (9/2004) highly commended the Unit on its exceptional performance for relative cost per weighted accrual, monitoring-source documentation, monitoring-endpoint determination, enrollment of Hispanics, laboratory shipping score, and timeliness of protocol registrations packets. As Dr. Sattler took over as Principal Investigator on 7/1/05, the CTU was reorganized. Several former ACTG, now mid-career investigators were recruited as Key Personnel, and several nationally renowned USC investigators with expertise in areas of high priority for Network research were included as Consultants and Collaborators. The primary goal of these changes was to augment the scientific contributions from the USC CTU with the expectation that the breadth and expertise of these investigators will provide a major impact in helping to shape the future CTN research agenda. This group of distinguished investigators includes 8 women and 5 faculty representing ethnic or racial minorities with expertise in clinical virology; immunology; mycology; tuberculosis; endocrinology/metabolism; hepatology; cardiology; adolescent and child care, women's health; and pharmacokinetics, pharmacodynamics and pharmacogenomics. Moreover, the USC CTU will continue its long-time commitment to the development of junior investigators, as Key Personnel will mentor 4 junior faculty or fellow-instructor trainees (2 women and 2 minority men) as CRS investigators in learning the principles of HIV clinical and translational research. Finally, this investigative group will allow the USC CTU/CRS to continue to perform at the same high level as in recent years in achieving the Network research agenda. They will also participate in ACTG group-wide meetings and contribute concept proposals for novel new treatment and prevention strategies to be tested in resource limited settings (e.g. East LA) that will often be applicable for the care of patients in developing countries. ? ? ADMINISTRATIVE COMPONENT: ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI069428-02
Application #
7450883
Study Section
Special Emphasis Panel (ZAI1-TP-A (M2))
Program Officer
Csedrik, Joanne E
Project Start
2007-07-01
Project End
2013-11-30
Budget Start
2007-12-01
Budget End
2008-11-30
Support Year
2
Fiscal Year
2008
Total Cost
$2,031,364
Indirect Cost
Name
University of Southern California
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Riddler, Sharon A; Aga, Evgenia; Bosch, Ronald J et al. (2016) Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. J Infect Dis 213:556-60
Dieli-Conwright, Christina M; Kiwata, Jacqueline L; Tuzon, Creighton T et al. (2016) Acute Response of PGC-1? and IGF-1 Isoforms to Maximal Eccentric Exercise in Skeletal Muscle of Postmenopausal Women. J Strength Cond Res 30:1161-70
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Lehmann, David S; Ribaudo, Heather J; Daar, Eric S et al. (2015) Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 25:51-9

Showing the most recent 10 out of 68 publications